A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses.
Cell Rep Med
; 2(4): 100245, 2021 04 20.
Article
in English
| MEDLINE | ID: covidwho-1155662
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and variants has led to significant mortality. We recently reported that an RNA-targeting CRISPR-Cas13 system, called prophylactic antiviral CRISPR in human cells (PAC-MAN), offered an antiviral strategy against SARS-CoV-2 and influenza A virus. Here, we expand in silico analysis to use PAC-MAN to target a broad spectrum of human- or livestock-infectious RNA viruses with high specificity, coverage, and predicted efficiency. Our analysis reveals that a minimal set of 14 CRISPR RNAs (crRNAs) is able to target >90% of human-infectious viruses across 10 RNA virus families. We predict that a set of 5 experimentally validated crRNAs can target new SARS-CoV-2 variant sequences with zero mismatches. We also build an online resource (crispr-pacman.stanford.edu) to support community use of CRISPR-Cas13 for broad-spectrum RNA virus targeting. Our work provides a new bioinformatic resource for using CRISPR-Cas13 to target diverse RNA viruses to facilitate the development of CRISPR-based antivirals.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
RNA Viruses
/
RNA, Guide, Kinetoplastida
/
CRISPR-Cas Systems
Type of study:
Prognostic study
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Cell Rep Med
Year:
2021
Document Type:
Article
Affiliation country:
J.xcrm.2021.100245
Similar
MEDLINE
...
LILACS
LIS